Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 333 LAKESIDE DR FOSTER CITY CA 94404 |
Tel: | N/A |
Website: | https://www.gilead.com |
IR: | See website |
Key People | ||
Daniel P O'Day Chairman of the Board, Chief Executive Officer | Andrew D. Dickinson Chief Financial Officer | Deborah H. Telman Executive Vice President - Corporate Affairs, General Counsel |
Johanna Mercier Chief Commercial Officer | Merdad V. Parsey Chief Medical Officer |
Business Overview |
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries. |
Financial Overview |
For the fiscal year ended 31 December 2023, Gilead Sciences, Inc. revenues decreased 1% to $27.12B. Net income applicable to common stockholders increased 23% to $5.67B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income reflects In-process research and development impa decrease of 98% to $50M (expense), Other Non Rec. I/E - Non Business act. decrease of 91% to $60M (expense). |
Employees: | 18,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $101,370M as of Dec 31, 2023 |
Annual revenue (TTM): | $27,116M as of Dec 31, 2023 |
EBITDA (TTM): | $11,506M as of Dec 31, 2023 |
Net annual income (TTM): | $5,664M as of Dec 31, 2023 |
Free cash flow (TTM): | $3,612M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $17,723M as of Dec 31, 2023 |
Shares outstanding: | 1,246,969,303 as of Mar 15, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |